查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239510

坐骨神經痛治療藥物市場：按類型、藥物類別和分銷渠道分類：全球機會分析和行業預測，2021-2031 年

Sciatica Treatment Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 241 Pages | 商品交期: 2-3個工作天內

價格

預計2021年坐骨神經痛治療藥物市場規模將達到6.7802億美元，2022-2031年復合年增長率為3.9%，2031年將達到9.9126億美元。

坐骨神經痛是指主要影響坐骨神經的疼痛，坐骨神經是從下背部延伸到臀部和腿部的神經。 坐骨神經痛通常只影響下半身的一側，但沿著神經路徑的任何地方都可能發生疼痛，從下背部到臀部再到大腿和小腿後部。 此外，坐骨神經痛的常見症狀包括坐著時腿部疼痛加劇、腿部灼痛或麻木，以及難以站立的疼痛。 此外，根據坐骨神經受影響的位置，您的腳和腳趾也可能會感到疼痛。 坐骨神經痛可以用多種藥物和止痛藥治療。 藥物包括消炎藥、止痛藥和抗驚厥藥。

推動坐骨神經痛藥物市場增長的主要因素是坐骨神經痛發病率的增加、開發新型坐骨神經痛治療方法的研發活動激增，以及人們對坐骨神經痛及其治療的關注。 在發展中國家和發達國家，坐骨神經痛的發病率都在增加，原因很多。 坐骨神經痛的主要原因是椎間盤突出、腰椎滑脫、椎間盤退變、椎管狹窄、腰椎滑脫。 根據約翰霍普金斯關節炎中心的數據，最近的人口估計表明美國強直性脊柱炎 (AS) 的患病率約為 0.2% 至 0.5%；對強直性脊柱炎 (AS) 的興趣正在增加，估計患病率為 0.4 至 14每 100,000 人。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 頂級影響因子
    • 頂級投資基金
  • 波特的五力分析
    • 供應商議價能力強
    • 買家議價能力適中
    • 替代品的威脅是中等的
    • 新進入者的威脅中等
    • 對手實力適中
  • 市場動態
    • 司機
      • 坐骨神經痛發病率上升
      • 老年人口增加
      • 增加研發活動
    • 約束因素
      • 存在或不存在替代治療
    • 機會
      • 新興國家的增長機會
  • 分析 COVID-19 對市場的影響

第 4 章坐骨神經痛藥物市場：按類型

  • 概覽
    • 市場規模和預測
  • 急性坐骨神經痛
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 慢性坐骨神經痛
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 5 章坐骨神經痛藥物市場：按藥物類別分類

  • 概覽
    • 市場規模和預測
  • 非甾體抗炎藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 類固醇
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 抗抑鬱藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 6 章坐骨神經痛藥物市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 零售藥店和專業藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 7 章坐骨神經痛藥物市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 歐洲
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 拉美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • LAMEA 的其餘部分
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道

第八章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第九章公司簡介

  • Abbott Laboratories
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sinfonia Biotherapeutics
  • Sorrento Therapeutics, Inc
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
Product Code: A13379

The sciatica treatment market size was valued for $678.02 million in 2021 and is estimated to reach $991.26 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Sciatica is referred to the pain that mainly affects sciatic nerves whereas sciatic nerves are the nerves that travel from the lower back through the hips and buttocks and down through each leg. Sciatica usually affects only one side of the lower body but the pain can occur in any part of the nerve pathway from the lower back to the buttock and the back of a thigh and calf. Furthermore, common symptoms of sciatica include pain in the leg which may worsen when sitting, burning or tingling down the leg, shooting pain that makes it difficult for the person to stand. Moreover, the pain may also occur in foot and toes, depending on the part of sciatic nerve affected. Sciatica can be treated using various medications or analgesic drugs. The medications include anti-inflammatory drugs, analgesic drugs, anti-convulsant and others.  

Major factors that drive the growth of the sciatica treatment market include increase in incidence of sciatica, surge in R&D activities for developing novel therapeutics for sciatica and rise in awareness among the people regarding sciatica and its treatments. There is an increase in incidence of sciatica in the developing and developed countries which have many different causes. Sciatica is mainly caused due to herniated or slipped disk, degenerative disk, spinal stenosis, spondylolisthesis and others. According to the Johns Hopkins Arthritis Center, in the recent population estimates indicate that the prevalence of ankylosing spondylitis (AS) in the U.S. is approximately 0.2-0.5% and based on data from multiple countries, the age- and sex-adjusted incidence of ankylosing spondylitis (AS) is 0.4-14 per 100,000 people.  

In addition, in a year about 2% of people get a herniated disk. When a herniated disk happens to a vertebra in lower back, it can press on the sciatic nerve leading to sciatica. Thus, huge prevalence of such conditions leads to increase in incidences of sciatica. This, in turn, propels the growth of the sciatica treatment market. 

In addition, increase in R&D activities in pharmaceutical field is driving the growth of the market. Major players are focusing on developing new drugs and APIs having application in sciatica treatment that are potent and efficient. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to academic and private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug therapies for sciatica and other diseases, which further propels the growth of the market. 

Although, various key factors are driving the growth of the market, few factors such as lack of specific approved treatments for sciatica and presence of alternate treatment options hinder the growth of the market. Alternate treatment options including the physiotherapy, and bracing along with surgical treatment restrict the growth of the sciatica treatment market. However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. For instance, countries such as China and India with huge population base and high patient pool offer lucrative opportunities for the market growth. 

The sciatica treatment market is segmented by type, treatment, distribution channel and region. By type, the market is categorized into acute sciatica, chronic sciatica and others. On the basis of drug class, the market is segregated into non-steroidal anti-inflammatory drug (NSAIDs), steroids, antidepressants, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail and specialty pharmacies and online providers.  

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the Abbott, Alkem Laboratories Limited, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnson & Johnson, Sinfonia Biotherapeutics, Sorrento Therapeutics, Inc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited and Zydus Group.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sciatica treatment market analysis from 2021 to 2031 to identify the prevailing sciatica treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the sciatica treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global sciatica treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acute sciatica
  • Chronic sciatica
  • Others

By Drug class

  • Non-steroidal anti-inflammatory drugs
  • Steroids
  • Antidepressants
  • Others

By Distribution channel

  • Hospital pharmacies
  • Retail and specialty pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Abbott Laboratories
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma
  • Sorrento Therapeutics, Inc
  • Alkem Laboratories Ltd
  • Amneal Pharmaceuticals LLC
  • Johnson and Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Sinfonia Biotherapeutics
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidence of sciatica
      • 3.4.1.2. Increase in geriatric population
      • 3.4.1.3. Increase in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Presence of alternate treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SCIATICA TREATMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Acute sciatica
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic sciatica
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: SCIATICA TREATMENT MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Non-steroidal anti-inflammatory drugs
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Steroids
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Antidepressants
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail and specialty pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SCIATICA TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Alkem Laboratories Ltd
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Amneal Pharmaceuticals LLC
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Johnson and Johnson
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Sinfonia Biotherapeutics
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Sorrento Therapeutics, Inc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Zydus Lifesciences Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Aurobindo Pharma
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. SCIATICA TREATMENT MARKET FOR STEROIDS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. SCIATICA TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. SCIATICA TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. U.S. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. CANADA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. MEXICO SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. EUROPE SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. GERMANY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. FRANCE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. UK SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ITALY SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SPAIN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF EUROPE SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. CHINA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. AUSTRALIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. SOUTH KOREA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. LAMEA SCIATICA TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. BRAZIL SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SAUDI ARABIA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SOUTH AFRICA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA SCIATICA TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF LAMEA SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 89. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 90. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 91. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 92. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 93. ALKEM LABORATORIES LTD: KEY EXECUTIVES
  • TABLE 94. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 95. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
  • TABLE 96. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 97. ALKEM LABORATORIES LTD: KEY STRATERGIES
  • TABLE 98. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 99. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 100. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 101. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 102. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 103. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 104. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
  • TABLE 105. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 106. SINFONIA BIOTHERAPEUTICS: KEY EXECUTIVES
  • TABLE 107. SINFONIA BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 108. SINFONIA BIOTHERAPEUTICS: PRODUCT SEGMENTS
  • TABLE 109. SINFONIA BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 110. SINFONIA BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 111. SORRENTO THERAPEUTICS, INC: KEY EXECUTIVES
  • TABLE 112. SORRENTO THERAPEUTICS, INC: COMPANY SNAPSHOT
  • TABLE 113. SORRENTO THERAPEUTICS, INC: PRODUCT SEGMENTS
  • TABLE 114. SORRENTO THERAPEUTICS, INC: PRODUCT PORTFOLIO
  • TABLE 115. SORRENTO THERAPEUTICS, INC: KEY STRATERGIES
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 121. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 122. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 129. AUROBINDO PHARMA: KEY EXECUTIVES
  • TABLE 130. AUROBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 131. AUROBINDO PHARMA: PRODUCT SEGMENTS
  • TABLE 132. AUROBINDO PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF SCIATICA TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN SCIATICA TREATMENT MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSCIATICA TREATMENT MARKET
  • FIGURE 10. SCIATICA TREATMENT MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ACUTE SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR CHRONIC SCIATICA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 14. SCIATICA TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR STEROIDS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. SCIATICA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR RETAIL AND SPECIALTY PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF SCIATICA TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. SCIATICA TREATMENT MARKET BY REGION, 2021
  • FIGURE 24. U.S. SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA SCIATICA TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: SCIATICA TREATMENT MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 51. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. ALKEM LABORATORIES LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. ALKEM LABORATORIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. JOHNSON AND JOHNSON: SALES REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. JOHNSON AND JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. JOHNSON AND JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. SORRENTO THERAPEUTICS, INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. SORRENTO THERAPEUTICS, INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. AUROBINDO PHARMA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 70. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)